Sale

Cardiovascular Drugs Market

Global Cardiovascular Drugs Market Size, Report: By Drug Class: Antihypertensive Drugs, Anticoagulants, Antiplatelet Agents, Antihyperlipidemic Drugs, Antiarrhythmic Drugs, Others; By Indications; By Route of Administration; By Drug Type; By End User; By Distribution Channel; Regional Analysis; Competitive Landscape; 2024-2032

Global Cardiovascular Drugs Market Outlook

The global cardiovascular drugs market size attained a value of USD 66.70 billion in 2023. The market is anticipated to grow at a CAGR of 2.7% during the forecast period of 2024-2032, driven by the rising prevalence of cardiovascular diseases across the globe. The global cardiovascular drugs market share is anticipated to achieve a value of USD 84.47 billion by 2032.

 

Global Cardiovascular Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America to Lead the Global Cardiovascular Drugs Market

North America dominates the global cardiovascular drugs industry, owing to the increased awareness about various heart diseases within the region. The United States represent the most important marketplace for cardiovascular drugs followed by Canada in North America. On the other hand, Asia Pacific is predicted to witness high growth rates in the coming years, thanks to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labour attracts manufacturing companies which is further boosting the growth in the Asia Pacific region.

Additionally, increasing awareness about heart related problems is supporting within the growth of cardiovascular drugs market within the region. China, India, and Japan are expected to be the fastest growing cardiovascular drugs markets thanks to rising cases of heart diseases and extensive pipeline drugs. Increasing ageing population and rising number of lifestyle diseases are also contributing to the growth of global cardiovascular drugs industry.

 

Cardio Vascular Drugs: Market Segmentation

Cardiovascular drugs refer to agents used for the treatment of diseases related to the cardiovascular system, which include blood clots, stroke, arteria coronaria disease, variation in vital sign, arrhythmias, high cholesterol, and coronary failure.

 

Global Cardiovascular Drugs Market By Drug Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Cardiovascular drugs can be divided on the basis of drug type into:

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiarrhythmics
  • Others

On the basis of disease indication, cardiovascular drugs can be divided into:

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

Cardiovascular drugs can be segmented on the basis of distribution channel into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

The regional markets for global cardiovascular drugs industry can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Cardiovascular Drugs Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Cases of Cardiovascular Diseases Boosting the Global Cardiovascular Drugs Industry

Cardiovascular drugs are extremely helpful in treating various heart related dysfunction. The rising prevalence of heart stroke and cardiovascular diseases is one among the key reasons for the expansion of the cardiovascular drugs market. Cardiovascular diseases have shown stable increase in prevalence worldwide, driven by numerous modern lifestyle changes. Factors like sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors liable for the rise within the number of cardiovascular disorders among the young population. A number of the opposite crucial drivers for global cardiovascular drugs industry growth is that the increased awareness regarding cardiovascular health and therefore the corresponding increase in product launches. The rising number of diabetic patients holds immense potential to the expansion of worldwide cardiovascular drugs industry.

 

Key Industry Players in the Global Cardiovascular Drugs Market

The report gives a detailed analysis of the following key players in the global cardiovascular drugs industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Group
  • Pfizer Inc.
  • Lupin
  • GSK Plc
  • Glenmark Pharmaceuticals Inc.
  • Capricor Therapeutics
  • Zensun

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Indications
  • Route of Administration
  • Drug Type
  • End User
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Antihypertensive Drugs
  • Anticoagulants
  • Antiplatelet Agents
  • Antihyperlipidemic Drugs
  • Antiarrhythmic Drugs
  • Others
Breakup by Indications
  • Hypertension
  • Coronary artery disease
  • Heart Failure
  • Arrhythmias
  • Dyslipidemia
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by Drug Type
  • Branded
  • Generics
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Breakup by Distribution Channel
  • Hospitals Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Group
  • Pfizer Inc.
  • Lupin
  • GSK Plc
  • Glenmark Pharmaceuticals Inc.
  • Capricor Therapeutics
  • Zensun

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Cardiovascular Drugs Market Overview

    3.1    Global Cardiovascular Drugs Market Historical Value (2017-2023) 
    3.2    Global Cardiovascular Drugs Market Forecast Value (2024-2032)
4    Global Cardiovascular Drugs Market Landscape
    4.1    Global Cardiovascular Drugs Company Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Cardiovascular Drugs Product Landscape
        4.2.1    Analysis by Drug Class
        4.2.2    Analysis by Indications
        4.2.3    Analysis by Route of Administration
        4.2.4    Analysis by End User
        4.2.5    Analysis by Distribution Channel
5    Global Cardiovascular Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Cardiovascular Drugs Market Segmentation
    6.1    Global Cardiovascular Drugs Market by Drug Class
        6.1.1    Market Overview
        6.1.2    Antihypertensive Drugs
        6.1.3    Anticoagulants
        6.1.4    Antiplatelet Agents
        6.1.5    Antihyperlipidemic Drugs
        6.1.6    Antiarrhythmic Drugs
        6.1.7    Others
    6.2    Global Cardiovascular Drugs Market by Indications
        6.2.1    Market Overview
        6.2.2    Hypertension
        6.2.3    Coronary artery disease
        6.2.4    Heart Failure
        6.2.5    Arrhythmias
        6.2.6    Dyslipidemia
        6.2.7    Others
    6.3    Global Cardiovascular Drugs Market by Route of Administration
        6.3.1    Market Overview
        6.3.2    Oral
        6.3.3    Parenteral
        6.3.4    Others
    6.4    Global Cardiovascular Drugs Market by Drug Type
        6.4.1    Market Overview
        6.4.2    Branded
        6.4.3    Generics
    6.5    Global Cardiovascular Drugs Market by End User
        6.5.1    Market Overview
        6.5.2    Hospitals
        6.5.3    Homecare
        6.5.4    Specialty Clinics
        6.5.5    Others
    6.6    Global Cardiovascular Drugs Market by Distribution Channel
        6.6.1    Market Overview
        6.6.2    Hospitals Pharmacy
        6.6.3    Online Pharmacy
        6.6.4    Retail Pharmacy
        6.6.5    Others
    6.7    Global Cardiovascular Drugs Market by Region
        6.7.1    Market Overview
        6.7.2    North America 
        6.7.3    Europe
        6.7.4    Asia Pacific
        6.7.5    Latin America
        6.7.6    Middle East and Africa
7    North America Cardiovascular Drugs Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Cardiovascular Drugs Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Cardiovascular Drugs Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Cardiovascular Drugs Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Cardiovascular Drugs Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    F. Hoffmann-La Roche Ltd.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Fresenius Kabi AG
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Bayer AG
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Sun Pharmaceutical Industries Ltd.
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Novartis AG
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Mylan N.V.
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Teva Pharmaceutical Industries Ltd.
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Zydus Group
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Pfizer Inc.
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Lupin
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    GSK Plc
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Glenmark Pharmaceuticals Inc.
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Capricor Therapeutics
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Zensun
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
18    Global Cardiovascular Drugs Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global cardiovascular drugs market is projected to grow at a CAGR of 2.7% between 2024 and 2032.

The major drivers of the market include the sedentary lifestyle, excess consumption of alcohol, stress and smoking, increased awareness regarding cardiovascular health, unhealthy eating habits, increasing ageing population, and rising number of lifestyle diseases.

The rising prevalence of heart stroke and cardiovascular diseases and the rising number of diabetic patients are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Cardiovascular drugs can be divided on the basis of drug type into antihypertensive, antihyperlipidemic, anticoagulants, and antiarrhythmics, among others.

Based on disease indication, cardiovascular drugs can be divided into hypertension, hyperlipidemia, coronary artery disease, and arrhythmia, among others.

The distribution channels include hospital pharmacies, retail pharmacies, and online, among others.

The major players in the industry are Baxter International Inc., Pfizer Inc., Bayer AG, Johnson & Johnson Services, Inc., Novartis AG, and Boehringer Ingelheim International GmbH, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER